Digital & Innovation

AI use in skin cancer management comes with a warning

Health Industry Hub | September 7, 2020 |
[Total: 1    Average: 4/5]

Digital & Innovation: Artificial intelligence (AI) use in dermatology is primed to become a powerful tool in skin cancer assessment, but it remains to be seen how diagnostic devices in dermatology will influence decision making in the clinic and affect patient outcomes, according to the Medical Journal of Australia.

In dermatology the primary focus for the use of AI has been on developing machine learning (ML) systems that facilitate classification and decision support for skin cancer management.

“Recent studies show that machine learning algorithms have the potential to surpass the diagnostic performance of experts, and the challenge now is how to implement this new technology safely into clinical practice,” wrote the authors, led by Associate Professor Victoria Mar, a consultant dermatologist and Director of the Victorian Melanoma Service at Alfred Hospital.

“There are two potentially negative implications for clinical practice: first, clinicians may have difficulty upskilling by following the algorithms’ outputs; and second, there exists the potential for deskilling and underperforming due to an over-reliance on technology.

“Algorithm performance is dependent on both the size and quality of the training image dataset and on whether the algorithm is used in situations for which it was intended,” wrote Mar and colleagues.

“The device may be limited in its ability to diagnose specific lesions (eg, non-pigmented), or lesions in certain skin types (eg, darker skin) or sites (eg, scalp or acral). Retrospective image databases used to train algorithms may be associated with bias. In addition, artefacts (eg, hair, dermoscopic gel, air bubbles, rulers, pen markings, reflections) can distract from key features.”

There has been a “striking” increase in the incidence of in situ melanoma over the past decade, from 32 cases per 100 000 population in 2004 to 80 per 100 000 population in 2019, with age-standardised mortality remaining fairly stable.

“For the purposes of screening for melanoma, AI-assisted targeted screening of high-risk individuals is likely to be a more effective strategy to save lives than the current opportunistic approach,” wrote Mar and colleagues.

“Our ability to identify lesions associated with sinister biological potential will improve, thereby reducing unnecessary biopsies, minimising overdiagnosis and other potential harms associated with screening.”

Using AI in clinical practice has advantages and disadvantages, Mar and colleagues wrote.

“An artificial intelligence system used as a triaging tool before clinician assessment would enable automated risk stratification of individuals and/or lesions. This approach could dramatically improve clinician workload and timely access to specialist care for people requiring urgent attention.

“Alternatively, artificial intelligence consulted following an examination by the clinician may act as a second opinion to improve diagnostic sensitivity and reduce unnecessary biopsies.

“The latter is more closely aligned with current clinical workflows and therefore likely to be preferred while the field matures,” they wrote.

“There is potential for over-reliance on artificial intelligence systems in both scenarios.”

In terms of safety, Mar and colleagues urged caution particularly in relation to smartphone applications available to the public.

“Some of these provide skin lesion risk assessment, although they may state that they are not intended to be used as a diagnostic device.

“There is concern that, if this is not immediately obvious to the consumer, unregistered applications may be used in lieu of seeking medical advice. Unsupervised consumer-operated diagnostic devices would require careful testing before they can be recommended.

“Ultimately, responsibility for patient care remains with the clinician and, as such, a high level of clinical acumen must be maintained,” they concluded.

About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

Marketing & Strategy

PRIME Award 2020 winners announced

Health Industry Hub | September 24, 2020 |

The first ever virtual PRIME Awards saw the best and brightest healthcare communications work recognised in the pharmaceutical and life […]


News & Trends - Pharmaceuticals

Pharma News - Australia’s first Antimicrobial Resistance Network to combat global health threat

Australia’s first Antimicrobial Resistance Network to combat global health threat

Health Industry Hub | September 24, 2020 |

Please log in to Health Industry Hub to view this content in the News menu → Pharmaceuticals sub-menu.


News & Trends - Medical Technology

MedTech News - Companies playing an important role in the robot-assisted surgery market

Companies playing an important role in the robot-assisted surgery market

Health Industry Hub | September 23, 2020 |

MedTech News: The market for surgical robots is expected to grow from USD 6.7 billion in 2020 to USD 11.8 […]


News & Trends - Pharmaceuticals

Pharma News - Roche acquires Inflazome co-founded by local researcher

Roche acquires Inflazome co-founded by local researcher

Health Industry Hub | September 23, 2020 |

Please log in to Health Industry Hub to view this content in the News menu → Pharmaceuticals sub-menu.